Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.
Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.